Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production

Article activity feed

1. Version published to 10.1186/s12916-022-02240-4

   Jan 19, 2022
2. 

   ScreenIT

   Sep 27, 2021

   SciScore for 10.1101/2021.09.17.21263726: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: This study was approved by the ethics committee of the Rostock University Medical Center under the file number A 2020-0086. Consent: Written informed consent was provided by all participants.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   In order to reduce unspecific antibody-conjugate binding, 10 µL FCS, 5 µL True-Stain Monocyte Blocker™ and 5 µL anti-Fc receptor TruStain FcX™ (Biolegend, San Diego/CA, United States) were added and incubated for 15 min on ice.	anti-Fc receptor TruStain FcX™ suggested: (BioLegend Cat# 422302, RRID:AB_2818986)
   The following amounts of …

   SciScore for 10.1101/2021.09.17.21263726: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IRB: This study was approved by the ethics committee of the Rostock University Medical Center under the file number A 2020-0086. Consent: Written informed consent was provided by all participants.
   Sex as a biological variable	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   In order to reduce unspecific antibody-conjugate binding, 10 µL FCS, 5 µL True-Stain Monocyte Blocker™ and 5 µL anti-Fc receptor TruStain FcX™ (Biolegend, San Diego/CA, United States) were added and incubated for 15 min on ice.	anti-Fc receptor TruStain FcX™ suggested: (BioLegend Cat# 422302, RRID:AB_2818986)
   The following amounts of antibody:fluorophore-combinations were used: 0.25 µg CD127:APC/R700 (clone HIL-7R-M21), 1 µg CD147:BV421 (TRA-1-85), 0.5 µg CD45RO:BV480 (UCHL1, BD Biosciences, Franklin Lakes/NJ, United States), 1 µg CD11b:PerCP/Cy5.5 (ICRF44), 0.8 µg CD11c:BV785 (3.9), 0.56 µg CD14:BV510 (	UCHL1 suggested: (BioLegend Cat# 304233, RRID:AB_11219394)
   Surface antigens were stained by incubating the cells with following antibody:fluorophore-combinations: 1.25 µg CD3:FITC (clone UCHT1), 0.02 µg CD4:BV750 (SK3), 0.06 µg CD8:BV570 (RPA-T8), 0.5 µg Fas-L:PE (NOK1), 1 µg CD25:APC (BC96, Biolegend), 1.25 µL CD127:APC/R700 (HIL-7R-M21) and 0.25 µg CD137:BV480 (4B4-1, BD Biosciences) for 15 min at room temperature.	antibody:fluorophore-combinations suggested: None NOK1 suggested: None BC96 suggested: None HIL-7R-M21 suggested: (BD Biosciences Cat# 566101, RRID:AB_2869742)
   Software and Algorithms
   Sentences	Resources
   Analysis of flow cytometry data was done using FlowJo software version 10.7 (FlowJo, Ashland/OR, United States).	FlowJo suggested: (FlowJo, RRID:SCR_008520)
   4.6 Statistical Analysis: Data analyses were performed using R (version 3.5.1) and InStat version 3.10 (GraphPad, San Diego/CA, United States).	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)
   Data visualization was performed with SigmaPlot version 13.0 (Systat Software GmbH, Erkrath, Germany).	SigmaPlot suggested: (SigmaPlot, RRID:SCR_003210)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   This study has a few limitations, among them the small samples sizes. Nonetheless, our results depict for both vaccines significantly disparate effects on the peripheral immune layout and on the regulation of T cell effector molecules. Another limitation is the lack of assaying neutralizing SARS-CoV-2 specific antibodies. However, previous studies have already demonstrated that total spike-binding Ig titers strongly correlate with the amounts of neutralizing antibodies and are therefore a suitable measure for humoral protection from SARS-CoV-2 infection5,40–42. In summary, we consider the description of disparate vaccine effects on the immediate immune response the strength of our study and we believe that our results will be of use for further optimization of vaccination strategies.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: Please consider improving the rainbow (“jet”) colormap(s) used on page 7. At least one figure is not accessible to readers with colorblindness and/or is not true to the data, i.e. not perceptually uniform.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
3. 

   Version published to 10.1101/2021.09.17.21263726v1 on medRxiv

   Sep 21, 2021